Immunotherapy for EBV-associated malignancies

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes

(2010) J. N. Barker et al.   BLOOD

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy

(2010) C. P. Fox et al.   BLOOD

Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation

(2010) K. P. Micklethwaite et al.   BLOOD

Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects

(2010) J. J. Melenhorst et al.   BLOOD

Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders

(2010) K. Jones et al.   BLOOD

Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells

(2010) A. Moosmann et al.   BLOOD

Allo-HLA reactivity of virus-specific memory T cells is common

(2010) A. L. Amir et al.   BLOOD

Adoptive T cell therapy of cancer

(2010) Malcolm K Brenner et al.   CURRENT OPINION IN IMMUNOLOGY

The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders

(2010) A. Merlo et al.   HAEMATOLOGICA

Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors

(2010) A. Merlo et al.   JOURNAL OF IMMUNOLOGY

Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma

(2010) Chrystal U. Louis et al.   JOURNAL OF IMMUNOTHERAPY

Allogeneic T-Cell Therapy for Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease: Long-Term Follow-Up

(2010) Tanzina Haque et al.   TRANSPLANTATION

Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease

(2009) J. Brewin et al.   BLOOD

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)

(2009) B. De Angelis et al.   BLOOD

CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells

(2009) H. M. Long et al.   BLOOD

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

(2009) A. M. Leen et al.   BLOOD

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes

(2009) P. J. Hanley et al.   BLOOD

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

(2009) H. E. Heslop et al.   BLOOD

Adoptive immunotherapy of cancer using CD4+ T cells

(2009) Pawel Muranski et al.   CURRENT OPINION IN IMMUNOLOGY

Epitope Specificity and Clonality of EBV-Specific CTLs Used to Treat Posttransplant Lymphoproliferative Disease

(2009) K. A. McAulay et al.   JOURNAL OF IMMUNOLOGY

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity

(2009) C. S. Hinrichs et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients

(2008) C. U. Louis et al.   BLOOD

IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes

(2008) S. Kaneko et al.   BLOOD

IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy

(2008) C. S. Hinrichs et al.   BLOOD

Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells

(2008) J. Klibi et al.   BLOOD

Induction of EBV-Latent Membrane Protein 1-Specific MHC Class II-Restricted T-Cell Responses against Natural Killer Lymphoma Cells

(2008) H. Kobayashi et al.   CANCER RESEARCH

Epstein-Barr virus nuclear antigen 1-specific CD4+T cells directly kill Epstein-Barr virus-carrying natural killer and T cells

(2008) Ayako Demachi-Okamura et al.   CANCER SCIENCE

Cytolytic mechanisms and T-cell receptor Vβ usage byex vivogenerated Epstein-Barr virus-specific cytotoxic T lymphocytes

(2008) Victoria J. Vanhoutte et al.   IMMUNOLOGY

Patients with Epstein Barr virus-positive lymphomas have decreased CD4+T-cell responses to the viral nuclear antigen 1

(2008) Kevin N. Heller et al.   INTERNATIONAL JOURNAL OF CANCER

Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-γ T cell responses

(2008) Ann M. Moormann et al.   INTERNATIONAL JOURNAL OF CANCER

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY

Epstein-Barr virus sustains tumor killers

(2008) Richard J O'Reilly   NATURE MEDICINE

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

(2008) Martin A Pule et al.   NATURE MEDICINE

Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products

(2008) Maaike E. Ressing et al.   SEMINARS IN CANCER BIOLOGY

T cell therapy of Epstein–Barr virus and adenovirus infections after hemopoietic stem cell transplant

(2007) P. Comoli et al.   BLOOD CELLS MOLECULES AND DISEASES